Genmab A/S ADS

GMABNASDAQ • USD
51.38 USD
↗ 0.03 (0.06%)🟢PRE MARKET (AS OF 07:09 AM EST)
🟢Market: OPEN

GMAB is currently priced at $51.38. The technical outlook is "Buy" based on moving average alignment, RSI, and MACD signals. Notable factors include a bullish Golden Cross on the moving averages and bullish moving average alignment.

Technical & fundamental data as of Nov 19, 2026.

Open?$51.13
High?$51.48
Low?$51.01
Prev. Close?$51.35
Volume?4.4K
Avg. Volume?N/A
VWAP?$51.28
Bid / Ask
Bid?$44.31 × 100
Ask?$58.79 × 100
Spread?$14.48
Midpoint?$51.55
Valuation & Ratios
Market Cap?31.4B
Shares Out?624.1M
P/E Ratio?N/A
P/B Ratio?N/A
EPS?N/A
Dividend?N/A
Ex-Dividend?N/A
News
Profile
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Employees
3.2K
Market Cap
31.4B
Industry
N/A
Listed
2010-10-05
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental Outlook
Loading...
Short InterestLow
Short Interest?9.7M
Days to Cover?1.2
Avg Daily Volume7.8M
Settlement Date2026-10-30